1-11 of 11
Heidi Simmons
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multilayer Profiling of MRD in Patients with Relapsed/Refractory CLL Treated with Venetoclax-Based Regimens in a Real-World Setting

Katia Pini, Alessio Bruscaggin, Maria Cristina Pirosa, Gabriela Forestieri, Joyce Marques de Almeida, Georg Stüssi, Mathias Oertli, Xenia Schmidt, Johannes Huelsenbeck, Thomas Noesslinger, Ingo Schwaner, Monica Gallucci, Heidi Simmons, Davide Rossi, Adalgisa Condoluci
Journal: Blood
Blood (2023) 142 (Supplement 1): 3257.
https://doi.org/10.1182/blood-2023-180509
Published: 2023
Journal Articles

Impact of Sequence Uniqueness on MRD Monitoring in NGS Immunoglobulin Sequencing: An Analysis of Ig Loci Among >1200 Diffuse Large B-Cell Lymphoma Patients Tested By Clonoseq

Heidi Simmons, Lik Wee Lee, April Lo, Kipp Akers, Ilan M. Kirsch, Allison P. Jacob
Journal: Blood
Blood (2023) 142 (Supplement 1): 5029.
https://doi.org/10.1182/blood-2023-190570
Published: 2023
Journal Articles

Update for the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Andrew J. Cowan, Krish Patel, Jakub Svoboda, Bijal D. Shah, Bruce D. Cheson, Georges Azzi, Viral Rabara, Lori S. Muffly, Heidi Simmons, Stephen Thuillier, Jessica T. Leonard
Journal: Blood
Blood (2023) 142 (Supplement 1): 3777.
https://doi.org/10.1182/blood-2023-187586
Published: 2023
Journal Articles

MRD Assessment in Patients with Newly Diagnosed Multiple Myeloma Using Tokenized Real World Data Sources

Miao Jiang, Anthony Hewitt, Jorge Zuloaga, Aaron Neiderhiser, Thu Xuan Vu, Heidi Simmons
Journal: Blood
Blood (2023) 142 (Supplement 1): 2339.
https://doi.org/10.1182/blood-2023-180986
Published: 2023
Journal Articles

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang, George Wright, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Svetlana Pack, Cody J Peer, Oluwatobi Arisa, Esther Mena, Maria L. Lindenberg, Ethan Bergvall, Craig A. Portell, Rafic J Farah, Seung Tae Lee, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Anna M Juanitez, Crystal Lu, Allison P. Jacob, Heidi Simmons, William D Figg, Seth M. Steinberg, Elaine S Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 434.
https://doi.org/10.1182/blood-2023-180173
Published: 2023
Journal Articles

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Ben A Derman, Tadeusz Kubicki, Heidi Simmons, Aimaz Afrough, Jeffrey A. Zonder, David L. Grinblatt, Larry D. Anderson, Jr., Andrew Kin, Sunil Narula, Shayan Rayani, Sandeep Gurbuxani, Theodore Karrison, Ken Jiang, Ajay Major, Jennifer H Cooperrider, Allison P. Jacob, Andrzej J Jakubowiak
Journal: Blood
Blood (2023) 142 (Supplement 1): 1982.
https://doi.org/10.1182/blood-2023-182410
Published: 2023
Journal Articles

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Neil Berinstein, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Monica Gallucci, Heidi Simmons
Journal: Blood
Blood (2023) 142 (Supplement 1): 3037.
https://doi.org/10.1182/blood-2023-186347
Published: 2023
Journal Articles

Interim Update on the 'Watch' Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Krish Patel, Jakub Svoboda, Bijal D. Shah, Bruce D. Cheson, Georges Azzi, Kashyap Patel, Andrew J Cowan, Lori Muffly, Heidi Simmons, Mark Schliekelman, Jessica Leonard
Journal: Blood
Blood (2022) 140 (Supplement 1): 5192–5194.
https://doi.org/10.1182/blood-2022-167669
Published: 2022
Journal Articles

MRD Assessment Using Next-Generation Sequencing (clonoSEQ® Assay) Among Fee-for-Service Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma Who Received Transplant

Miao Jiang, Peter Kardel, Irene Varghese, Anthony Hewitt, Heidi Simmons, Benjamin Eckert
Journal: Blood
Blood (2022) 140 (Supplement 1): 13102–13104.
https://doi.org/10.1182/blood-2022-170116
Published: 2022
Journal Articles

Real World Observational Study Using Clonoseq® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry

Krish Patel, MD, Neil Bailey, MSc, Cristina J. Gasparetto, MD, Tomer Mark, MD MSc, Bijal Shah, MD, Jakub Svoboda, MD, Michael A. Thompson, MD PhD, Heidi Simmons, PhD, Mark Schliekelman, PhD, Allison P. Jacob, Lance Baldo, MD, John M. Pagel, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37.
https://doi.org/10.1182/blood-2020-141440
Published: 2020
Journal Articles

A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.

Guillermo Garcia-Manero, MD, H. Jean Khoury, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Tapan Kadia, MD, Zeev Estrov, MD, Elias Jabbour, MD, Maria Cielo Foudray, RN, Martha Arellano, Amelia Langston, MD, Beverly Bethelmie-Bryan, Selena Rush, Burgess Freeman, Heidi Simmons, PhD, Mieke Ptaszynski, Hagop Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 2047.
https://doi.org/10.1182/blood.V114.22.2047.2047
Published: 2009